Brief: Iteos Announces First Patient Dosed In Galaxies Lung-301 Phase 3 Study, Earning $35 Mln In Milestones From GSK
08/07/2024 13:12
July 8 (Reuters) - Iteos Therapeutics Inc ITOS.O :
* ITEOS ANNOUNCES FIRST PATIENT DOSED IN GALAXIES LUNG-301
PHASE 3
STUDY, EARNING $35 MILLION IN MILESTONES FROM GSK
Source text for Eikon: ID:nGNX1s6rtr
Further company coverage: ITOS.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on iTeos Therapeutics
See all newsIteos Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Iteos Therapeutics Inc expected to post a loss of $1.01 a share - Earnings Preview
Brief: Iteos Therapeutics Enters Into Agreement To Be Acquired By Concentra Biosciences For $10.047 In Cash Per Share Plus A Contingent Value Right
U.S. STOCKS ON THE MOVE-Nvidia, Salesforce, Kestrel Group
U.S. STOCKS ON THE MOVE-Dick's Sporting Goods, Sonic Automotive